Survival effect of perioperative systemic chemotherapy on overall mortality in locally advanced and/or positive regional lymph node non-metastatic urothelial carcinoma of the upper urinary tract: World Journal of Urology

S Nazzani; F Preisser; E Mazzone; Z Tian; FA Mistretta; SF Shariat; D Soulières; F Saad; E Montanari; S Luzzago; A Briganti; L Carmignani; PI Karakiewicz

doi:10.1007/s00345-018-2516-z

Survival effect of perioperative systemic chemotherapy on overall mortality in locally advanced and/or positive regional lymph node non-metastatic urothelial carcinoma of the upper urinary tract: World Journal of Urology

S Nazzani, F Preisser, E Mazzone, Z Tian, FA Mistretta, SF Shariat, D Soulières, F Saad, E Montanari, S Luzzago, A Briganti, L Carmignani, PI Karakiewicz

IRCCS Ospedale San Raffaele

Research output: Contribution to journal › Article › peer-review

Abstract

Objectives: To analyze the potential survival benefit of perioperative chemotherapy (CHT) in patients treated with nephroureterectomy (NU) for non-metastatic locally advanced upper tract urothelial carcinoma. Methods: Within the Surveillance, Epidemiology, and End Results database (2004–2014), we identified 1286 patients with T3 or T4, N 0–3 M0 UTUC. Kaplan–Meier plots, as well as multivariable Cox regression models (MCRMs) relying on inverse probability after treatment weighting (IPTW) and landmark analyses, were used to test the effect of CHT vs no CHT on overall mortality (OM) in the overall population (n =1286), as well as after stratification according to lymph node invasion (LNI). Results: Overall, 37.4% patients received CHT. The CHT rate was higher with LNI (62.2% vs 35.2%, p

Original language	English
Pages (from-to)	1329-1337
Number of pages	9
Journal	World J. Urol.
Volume	37
Issue number	7
DOIs	https://doi.org/10.1007/s00345-018-2516-z
Publication status	Published - 2019

Access to Document

10.1007/s00345-018-2516-z

http://www.scopus.com/inward/record.url?scp=85054715261&partnerID=8YFLogxK

Fingerprint Dive into the research topics of 'Survival effect of perioperative systemic chemotherapy on overall mortality in locally advanced and/or positive regional lymph node non-metastatic urothelial carcinoma of the upper urinary tract: World Journal of Urology'. Together they form a unique fingerprint.

Cite this

Nazzani, S., Preisser, F., Mazzone, E., Tian, Z., Mistretta, FA., Shariat, SF., Soulières, D., Saad, F., Montanari, E., Luzzago, S., Briganti, A., Carmignani, L., & Karakiewicz, PI. (2019). Survival effect of perioperative systemic chemotherapy on overall mortality in locally advanced and/or positive regional lymph node non-metastatic urothelial carcinoma of the upper urinary tract: World Journal of Urology. World J. Urol., 37(7), 1329-1337. https://doi.org/10.1007/s00345-018-2516-z

Survival effect of perioperative systemic chemotherapy on overall mortality in locally advanced and/or positive regional lymph node non-metastatic urothelial carcinoma of the upper urinary tract : World Journal of Urology. / Nazzani, S; Preisser, F; Mazzone, E; Tian, Z; Mistretta, FA; Shariat, SF; Soulières, D; Saad, F; Montanari, E; Luzzago, S; Briganti, A; Carmignani, L; Karakiewicz, PI.

In: World J. Urol., Vol. 37, No. 7, 2019, p. 1329-1337.

Research output: Contribution to journal › Article › peer-review

Nazzani, S, Preisser, F, Mazzone, E, Tian, Z, Mistretta, FA, Shariat, SF, Soulières, D, Saad, F, Montanari, E, Luzzago, S, Briganti, A, Carmignani, L & Karakiewicz, PI 2019, 'Survival effect of perioperative systemic chemotherapy on overall mortality in locally advanced and/or positive regional lymph node non-metastatic urothelial carcinoma of the upper urinary tract: World Journal of Urology', World J. Urol., vol. 37, no. 7, pp. 1329-1337. https://doi.org/10.1007/s00345-018-2516-z

Nazzani S, Preisser F, Mazzone E, Tian Z, Mistretta FA, Shariat SF et al. Survival effect of perioperative systemic chemotherapy on overall mortality in locally advanced and/or positive regional lymph node non-metastatic urothelial carcinoma of the upper urinary tract: World Journal of Urology. World J. Urol. 2019;37(7):1329-1337. https://doi.org/10.1007/s00345-018-2516-z

Nazzani, S ; Preisser, F ; Mazzone, E ; Tian, Z ; Mistretta, FA ; Shariat, SF ; Soulières, D ; Saad, F ; Montanari, E ; Luzzago, S ; Briganti, A ; Carmignani, L ; Karakiewicz, PI. / Survival effect of perioperative systemic chemotherapy on overall mortality in locally advanced and/or positive regional lymph node non-metastatic urothelial carcinoma of the upper urinary tract : World Journal of Urology. In: World J. Urol. 2019 ; Vol. 37, No. 7. pp. 1329-1337.

@article{f77ea17ae45548bdb70bd7afb0bf604b,

title = "Survival effect of perioperative systemic chemotherapy on overall mortality in locally advanced and/or positive regional lymph node non-metastatic urothelial carcinoma of the upper urinary tract: World Journal of Urology",

abstract = "Objectives: To analyze the potential survival benefit of perioperative chemotherapy (CHT) in patients treated with nephroureterectomy (NU) for non-metastatic locally advanced upper tract urothelial carcinoma. Methods: Within the Surveillance, Epidemiology, and End Results database (2004–2014), we identified 1286 patients with T3 or T4, N 0–3 M0 UTUC. Kaplan–Meier plots, as well as multivariable Cox regression models (MCRMs) relying on inverse probability after treatment weighting (IPTW) and landmark analyses, were used to test the effect of CHT vs no CHT on overall mortality (OM) in the overall population (n =1286), as well as after stratification according to lymph node invasion (LNI). Results: Overall, 37.4% patients received CHT. The CHT rate was higher with LNI (62.2% vs 35.2%, p ",

author = "S Nazzani and F Preisser and E Mazzone and Z Tian and FA Mistretta and SF Shariat and D Souli{\`e}res and F Saad and E Montanari and S Luzzago and A Briganti and L Carmignani and PI Karakiewicz",

year = "2019",

doi = "10.1007/s00345-018-2516-z",

language = "English",

volume = "37",

pages = "1329--1337",

journal = "World J. Urol.",

issn = "0724-4983",

publisher = "Springer Verlag",

number = "7",

}

TY - JOUR

T1 - Survival effect of perioperative systemic chemotherapy on overall mortality in locally advanced and/or positive regional lymph node non-metastatic urothelial carcinoma of the upper urinary tract

T2 - World Journal of Urology

AU - Nazzani, S

AU - Preisser, F

AU - Mazzone, E

AU - Tian, Z

AU - Mistretta, FA

AU - Shariat, SF

AU - Soulières, D

AU - Saad, F

AU - Montanari, E

AU - Luzzago, S

AU - Briganti, A

AU - Carmignani, L

AU - Karakiewicz, PI

PY - 2019

Y1 - 2019

N2 - Objectives: To analyze the potential survival benefit of perioperative chemotherapy (CHT) in patients treated with nephroureterectomy (NU) for non-metastatic locally advanced upper tract urothelial carcinoma. Methods: Within the Surveillance, Epidemiology, and End Results database (2004–2014), we identified 1286 patients with T3 or T4, N 0–3 M0 UTUC. Kaplan–Meier plots, as well as multivariable Cox regression models (MCRMs) relying on inverse probability after treatment weighting (IPTW) and landmark analyses, were used to test the effect of CHT vs no CHT on overall mortality (OM) in the overall population (n =1286), as well as after stratification according to lymph node invasion (LNI). Results: Overall, 37.4% patients received CHT. The CHT rate was higher with LNI (62.2% vs 35.2%, p

AB - Objectives: To analyze the potential survival benefit of perioperative chemotherapy (CHT) in patients treated with nephroureterectomy (NU) for non-metastatic locally advanced upper tract urothelial carcinoma. Methods: Within the Surveillance, Epidemiology, and End Results database (2004–2014), we identified 1286 patients with T3 or T4, N 0–3 M0 UTUC. Kaplan–Meier plots, as well as multivariable Cox regression models (MCRMs) relying on inverse probability after treatment weighting (IPTW) and landmark analyses, were used to test the effect of CHT vs no CHT on overall mortality (OM) in the overall population (n =1286), as well as after stratification according to lymph node invasion (LNI). Results: Overall, 37.4% patients received CHT. The CHT rate was higher with LNI (62.2% vs 35.2%, p

U2 - 10.1007/s00345-018-2516-z

DO - 10.1007/s00345-018-2516-z

M3 - Article

VL - 37

SP - 1329

EP - 1337

JO - World J. Urol.

JF - World J. Urol.

SN - 0724-4983

IS - 7

ER -